RO7851624: Participants will receive RO7851624 as per the schedule described in the protocol.
Study summary
This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \[PIs\], immunomodulators \[IMiDs\], and anti-cluster of differentiation 38 \[anti-CD38\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Life expectancy of at least 12 weeks.
* Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.
* Measurable disease.
Exclusion Criteria:
* Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to first dose of study treatment.
* Autologous stem cell transplant (SCT) with insufficient time prior to first dose of study treatment.
* Prior allogeneic SCT.
* Prior solid organ transplantation.
Primary outcome measure(s)
Percentage of Participants With Adverse Events (AEs) — Up to approximately 2 years
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.